Emicizumab PUPs and Nuwiq ITI Study

This study prospectively investigates the safety, FVIII immunogenicity, and hemostatic efficacy of prophylactic HEMLIBRA® given with a concomitant low dose recombinant factor VIII (rFVIII) known as NUWIQ®, in HA infants and children <3 years old who have had little to no previous exposure to FVIII. In addition, the study investigates the safety and efficacy of a novel FVIII ITI regimen in children <21 with existing low and high titer inhibitors (LTI and HTI).

Study Overview

• Status: Withdrawn
• Conditions: Hemophilia A
• Intervention / Treatment: Drug: Nuwiq (low dose protocol); Drug: HEMLIBRA; Drug: Nuwiq (Atlanta protocol)

Detailed Description

Hemophilia A (HA) is a congenital bleeding disorder caused by deficient or dysfunctional factor VIII (FVIII) which leads to bleeding correlated with severity. Management is focused on FVIII replacement in reaction to a bleed or preventive as prophylaxis. Effective treatment is complicated by the: (1) difficulty to administer standard replacement therapy via intravenous injection especially in infants and young children; and (2) development of inhibitors (FVIII neutralizing antibodies). Inhibitors can increase morbidity and mortality and exponentially raise the cost of health care. Although inherited and environmental risk factors for inhibitor formation have been identified, there is no effective strategy to prevent inhibitors from developing. Emicizumab (HEMLIBRA®) was recently approved by the Food and Drug Administration (FDA) in infants, children, and adults with congenital hemophilia A, with and without inhibitors, and offers hemostatic efficacy while reducing the burden of administration since it is given weekly, biweekly (every 2 weeks), or monthly via subcutaneous (SQ) route compared to the intravenous (IV) route of FVIII.

This study prospectively investigates the safety, FVIII immunogenicity, and hemostatic efficacy of prophylactic HEMLIBRA® given with a concomitant low dose recombinant factor VIII (rFVIII) known as NUWIQ®, in HA infants and children <3 years old who have had little to no previous exposure to FVIII. In addition, the study investigates the safety and efficacy of a novel FVIII ITI regimen in children <21 with existing low and high titer inhibitors (LTI and HTI).

• Study Type: Interventional
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Robert Sidonio, MD; Phone Number: 404-785-1637; Email: robert.sidonio.jr@emory.edu

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90027
      • Children's Hospital Los Angeles
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Emory University/Children's Healthcare of Atlanta
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • Mindy_L_Simpson@rush.edu
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Children's Hospital of Michigan/ Wayne State University
  • New York
    • New York, New York, United States, 10021
      • Weill Cornell Medicine
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • University of North Carolina - Hemophilia and Thrombosis Center
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53233
      • Verisiti, WI

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 21 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria - Part A:

• Moderately severe (≤2% FVIII) hemophilia A
• <3 Years of age at the time of informed consent
• Caregiver (parent or legal guardian) has provided written informed consent
• ≤2 EDs to pdFVIII, rFVIII, or a single dose of FFP, Cryoprecipitate or PRBCs.
• Adequate hematologic function (HgB >8 g/dL and platelet count >100,000 µL)
• Adequate hepatic function (total bilirubin ≤1.5x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's)
• Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min)
• Negative test for inhibitor (<0.6 BU/mL) with a 72-hour washout within 4 weeks of enrollment
• No documented FVIII inhibitor since birth *Participants will be encouraged to co-enroll in the ATHN 8 Study

Inclusion Criteria - Part B

• Moderately severe (≤2% FVIII) hemophilia A
• <21 Years of age at the time of informed consent
• Documented on 2 occasions a persistent low (>0.6 BU/mL) titer inhibitor with a 72-hour washout within 24 weeks of enrollment or historical high titer inhibitor (>5 BU/mL) and a single occasion of a low titer inhibitor (>0.6 BU/mL) with a 72-hour washout within 24 weeks of enrollment after either the first time ITI or after single attempt of <6 months of continuous 3x/week factor ITI
• Has completed loading doses of HEMLIBRA® (weekly for 4 weeks, dose 3 mg/kg, a total of 12 mg/kg/dose will also be allowed)
• Caregiver and/or participant provided written informed consent
• Adequate hematologic function (HgB >8 g/dL and platelet count >100,000 µL)
• Adequate hepatic function (total bilirubin ≤1.5x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's)
• Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min)

Exclusion Criteria - Part A and B

• Inherited or acquired bleeding disorder other than severe hemophilia A (participants with previous documentation of low von Willebrand factor (vWF) defined as vWF antigen and vWF ristocetin cofactor both between 40-50 will be permitted)
• Previous or current treatment for thromboembolic disease or signs of thromboembolic disease
• Conditions that may increase the risk of bleeding or thrombosis. Will not require or request a thrombophilia evaluation
• History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the HEMLIBRA® injection (with the exception of rituximab)
• Known HIV infection with CD4 count <200 cells/µL within 24 weeks prior to screening. Testing is not required if can demonstrate negative testing in the mother prior to pregnancy
• Use of systemic immunomodulators at enrollment or planned use during the study
• Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment
• Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose an additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study
• Planned surgery (excluding minor procedures or central line placement) during the study
• Receipt of HEMLIBRA® as part of a prior investigational study; an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of the last drug administration; a non-hemophilia-related investigational drug concurrently, within the last 30 days or 5 half-lives, whichever is shorter

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Untreated/minimally treated moderate HA no inhibitors; Previously untreated patients (PUPs) and minimally treated patients (MTPs) <3 years of age with moderately severe (≤2% FVIII) HA and no inhibitors.	Drug: Nuwiq (low dose protocol); After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.; Other Names: Simoctocog alfa; Drug: HEMLIBRA; Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.; Other Names: Emicizumab, ACE910, and RO5534262
Experimental: Treated any moderate HA with existing inhibitors; Children <21 years of age with moderately severe (≤2% FVIII) HA and with already existing inhibitors (LTI or HTI).	Drug: HEMLIBRA; Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.; Other Names: Emicizumab, ACE910, and RO5534262; Drug: Nuwiq (Atlanta protocol); After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.; Other Names: Simoctocog alfa

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative incidence of inhibitors to FVIII	Cumulative incidence of inhibitors to FVIII will be recorded	Duration of the follow up (up to 36 months)
Number of Immune Tolerance Induction (ITI) success cases	ITI success case is confirmed if three of below are criteria met: Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements; FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection; Half-life of FVIII ≥ 6 h	Duration of the follow up (up to 36 months)
Number of Immune Tolerance Induction (ITI) partial success cases	ITI partial success case is confirmed if two of below criteria are met: Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements; FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection; Half-life of FVIII ≥ 6 h	Duration of the follow up (up to 36 months)
Number of Immune Tolerance Induction (ITI) partial response cases	ITI partial response case is confirmed if one of below criteria is met: Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements; FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection; Half-life of FVIII ≥ 6 h	Duration of the follow up (up to 36 months)
Number of Immune Tolerance Induction (ITI) partial failure cases	ITI partial failure case is confirmed if none of below criteria are met, but participant who initially had a high-titre inhibitor (≥ 5 BU/mL) has a low-titre inhibitor (< 5 BU/mL) at end of ITI.; Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements; FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection; Half-life of FVIII ≥ 6 h	Duration of the follow up (up to 36 months)
Number of Immune Tolerance Induction (ITI) failure cases	ITI failure case is confirmed if none of below criteria are met: Inhibitor titre < 0.6 BU/mL for at least 2 consecutive measurements; FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg BW approximately 15 to 30 min post-injection; Half-life of FVIII ≥ 6 h	Duration of the follow up (up to 36 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of target joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks)	Number of target joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks) will be recorded	12 months follow up
Annualized bleeding rate (ABR)	Number of bleeding events over time (bleed rate) will be recorded to calculate ABR to determine hemostatic efficacy of treatment regiments. Annualized bleeding rate (bleeds/year) is calculated as the number of bleeding events divided by length of time of the treatment regimen.	Duration of the follow up (up to 36 months)
Number of adverse events	Number of adverse events (AEs and SAEs) will be recorded to evaluate safety of treatment regiments	Duration of the follow up (up to 36 months)
Change in blood levels of anti-FVIII antibodies	Blood test will be done to evaluate blood levels of anti-FVIII antibodies	Weekly x4 (±3 days), then monthly (±7 days) up to 36 months
Change in blood levels of anti-Emicizumab antibodies	Blood test will be done to evaluate blood levels of anti-Emicizumab antibodies	Weekly x4 (±3 days), then monthly (±7 days) up to 36 months
Number of infusions of Nuwiq/Novo7 for treatment of an acute bleeding episode	Number of infusions of Nuwiq/Novo7 for treatment of an acute bleeding episode will be recorded	Duration of the follow up (up to 36 months)
Number of infusions of rFVIII or rFVIIa for treatment of an acute bleeding episode	Number of infusions of rFVIII or rFVIIa for treatment of an acute bleeding episode will be recorded	Duration of the follow up (up to 36 months)
Change in blood levels of emicizumab (HEMLIBRA®) in young children (1 month to 24 months of age)	Blood levels of emicizumab (HEMLIBRA®) in young children (1 month to 24 months of age) will be measured to study Emicizumab pharmacokinetics	Weekly for 4 weeks, monthly for 5 months, and every 3 months until study end (up to 36 months)
Microbiota composition of stool in infants with vs. without inhibitors	Microbiota composition of stool in infants with vs. without inhibitors will be measured	Duration of the follow up (up to 36 months)
Change in CATCH scale score	Scores are calculated as the mean of scores for all items, if 50% or more of the items are missing, then the score is set at missing. CATCH scores range from 0 to 100, with the following interpretation: Higher score = Higher the perceived risk to have a bleed while doing daily activities; Higher score = Higher impact of hemophilia on daily activities; Higher score = Higher the perceived risk to have a bleed while doing social activities; Higher score = Higher impact of hemophilia on social activities; Higher score = Higher the perceived risk to have a bleed while doing recreational activities; Higher score = Higher impact of hemophilia on recreational activities; Higher score = Higher impact of hemophilia on work/school activities; Higher score = Greater preoccupation related to hemophilia; Higher score = Greater perceived burden of the hemophilia treatment	Baseline, 36 months
Change in Adapted Inhib-QoL scale score	Adapted Inhib-QoL scores range from 0 to 100, with lower scores reflecting better health-related quality of life	Baseline, 36 months
Number of joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks)	Number of joint bleeding events over time (≥3 bleeds in the same joint over the last 24 weeks) will be recorded	6 months follow up

Collaborators and Investigators

• Sponsor: Emory University
• Collaborators: Genentech, Inc.
• Investigators: Principal Investigator: Robert Sidonio, MD, Emory University

Study record dates

Study Major Dates

• Study Start (Actual): February 17, 2022
• Primary Completion (Actual): January 19, 2023
• Study Completion (Actual): January 19, 2023

Study Registration Dates

• First Submitted: July 21, 2019
• First Submitted That Met QC Criteria: July 21, 2019
• First Posted (Actual): July 23, 2019

Study Record Updates

• Last Update Posted (Actual): January 5, 2024
• Last Update Submitted That Met QC Criteria: January 3, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: safety; children; infants; immunogenicity; hemostasis; hemophilia; prophylactic; hemostatic efficacy
• Additional Relevant MeSH Terms: Hematologic Diseases; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Blood Coagulation Disorders; Hemophilia A; Coagulants; Factor VIII
• Other Study ID Numbers: IRB00111805

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All of the individual participant data that underlie the results reported in the article, after deidentification (text, tables, figures and appendices) will be shared.
• IPD Sharing Time Frame: Data will become available beginning 9 months and ending 36 months after publication
• IPD Sharing Access Criteria: Data will be shared with investigators/researchers involved in the study approved by the steering committee following verification of sound science for the purpose of achieving aims of the study, meta-analysis and for sound scientific evaluation deemed by the steering committee. Proposal may be submitted up to 36 months following publication and can be accessed following steering committee approval directed to Traci Leong (tleong@emory.edu), the statistician.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No